Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris

American Journal of Cardiovascular Drugs

Volumn 13, Issue 6, 2013, Pages 407-412

  Ling, Hua ^a   Packard, Kathleen A ^a   Burns, Tammy L ^a   Hilleman, Daniel E ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; NITRATE; RANOLAZINE;

AGED; ANGINA PECTORIS; ARTICLE; CONSTIPATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HEADACHE; HEALTH CARE UTILIZATION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT OUTCOME;

ACETANILIDES; AGED; ANGINA PECTORIS; FEMALE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RETROSPECTIVE STUDIES; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME;

EID: 84890497041     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0038-z     Document Type: Article

References (18)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245.
2. McGillion M, Arthur HM, Cook A, et al. Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society Joint Guidelines. Can J Cardiol. 2012;28:S20-41.
3. Bhatt AB, Stone PH. Current strategies for the prevention of angina in patients with stable coronary artery disease. Curr Opin Cardiol. 2006;21:492-502.
4. Soran O. Treatment options for refractory angina pectoris: enhanced external counterpulsation therapy. Curr Treat Options Cardiovasc Med. 2009;11:54-60.
5. Kim MC, Kini A, Sharma S. Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol. 2002;39:923-34.
6. Stewart S, Murphy N, Walker A. McGuire A, McMurray JJV. The current cost of angina pectoris to the National Health Service in the UK. Heart. 2003; 89:848-53.
7. McGillion M, Croxford R, Watt-Watson J, Stevens B, LeFort S, Coyte P. Cost of illness for chronic angina pectoris patients enrolled in a self management education trial. Can J Cardiol. 2008;24:759-64.
8. Vadnais D, Wenger NK. Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Mgt. 2010;6:517-30.
9. Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010;56:934-42.
10. Hawwa N, Menon V. Ranolazine: clinical applications and therapeutic basis. Am J Cardiovasc Drugs. 2013;13:5-16.
11. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-82.
12. Chaitman BR, Pepine CJ, Parker CO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-16.
13. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina Trial). J Am Coll Cardiol. 2006;48:566-75.
14. Greene RS, Rangel RM, Edwards KL, et al. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovasc Revasc Med. 2012;13(2):141.e1-5.
15. Reeder DN, Gilette MA, Franck AJ, Frohnapple DJ. Clinical experience with ranolazine in a veteran population with chronic stable angina. Ann Pharmacotherapy. 2012;46:42-50.
16. Bennett NM, Arndt TL, Iyer V, et al. Ranolazine refractory angina registry trial: 1 year results. J Am Coll Cardiol. 2011; 57: E1050 (abstract).
17. Phelps CE, Buysman EK. Gomez Ray G. Costs and clinical outcomes associated with the use of ranolazine for treatment of angina. Clin Ther. 2012;34:1395-407.
18. Gilead Sciences. Ranolazine for incomplete vessel revascularization post-percutaneous coronary intervention (PCI) (RIVER-PCI). Available from: http://clinicaltrials.gov/show/NCT01442038. Accessed 16 July 2013.